ClinicalTrials.gg
CompletedNCT03430856Updated May 15, 2020Results posted

Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients

A Phase 2/3 interventional study of Insulin Tregopil and Insulin Aspart in Type2 Diabetes Mellitus, sponsored by Biocon Limited. Completed at 1 site in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-05-15.

Sponsored by Biocon Limited · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 403 studies in Diabetes Mellitus, Type 2 with a site in India — 33 open to participants now, 38 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · India.

Enrollment
278th of 342
143 · median 463
Started
2017
with 15 others
Phase 2/3
11 of 403
none open now
Registered
277th of 403
by date

Among the 403 studies in Diabetes Mellitus, Type 2 with a site in India, this one is the 278th largest by enrollment of the 342 interventional ones that give a count, is one of 16 that started in 2017, is one of 11 in phase 2/3, and was the 277th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

33 of the 403 studies in Diabetes Mellitus, Type 2 with a site in India are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Diabetes Mellitus, Type 2 with a site in India, or all of them as a file.
02

Study summary

This is an open label Phase II/III study to evaluate the efficacy and safety of test drug, Insulin Tregopil (IN-105) compared with Insulin Aspart (IAsp) in Type 2 Diabetes Mellitus patients. on stable dose of Metformin and insulin Glargine. The study will be conducted in 2 parts, Part I and Part II. The study duration will be approximately 37 weeks for Part I and for Part II of the study respectively

Read the detailed description

Part I of the study is a Phase II multi-center, randomized, open label clinical study to evaluate the efficacy and safety of Insulin Tregopil (2 dose levels: 30 mg, 45 mg) compared with IAsp in the treatment of T2DM patients. Part II of the study is the Phase III, multi-center, randomized, open label clinical study to evaluate the efficacy and safety of Insulin Tregopil (30 mg or 45 mg based upon the outcome of Part I data) compared with IAsp in the treatment of T2DM patients. For Part I and Part II, the study duration will be approximately 37 weeks (3 weeks Screening, 8 weeks Run-in, 24 weeks Treatment, 2 weeks Safety follow-up). An Independent Data and Safety Monitoring Board (DSMB) will evaluate the data from Part I of the study. Part II of the study will be initiated after approval from the office of Drugs Controller General of India (DCGI) and Data Safety Monitoring Board (DSMB) recommendation based on review of data from Part I of the study. In both Part I and Part II of the study, T2DM patients with glycated hemoglobin (HbA1c) 7.5 to 10% (both inclusive), on stable dose of metformin ± oral antidiabetic drugs (OADs) ± basal insulin who are eligible for insulin glargine administration as per investigator discretion and who satisfy the selection criteria will be enrolled. The eligible patients will go through a Run-in period of 8 weeks. At the end of 8 weeks Run-in period, eligibility will be checked and patients will enter the treatment period of 24 weeks and will be allocated to 3 treatment arms (Part I) or randomized to 2 treatment arms (Part II); if found eligible for randomization. A total of 90 patients in part 1 and 268 patients in part 2 will be randomised to the treatment arms from approximately 40 centers in India.

03

Conditions studied

  • Type2 Diabetes Mellitus

Keywords

  • Oral insulin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Patients with an established diagnosis of T2DM and a duration of diabetes mellitus of at least 6 months at Screening based on criteria given below as per American Diabetes Association (ADA) 2017 guidelines: i. ≥ 6.5% OR ii. FPG ≥ 126 mg/dL. (Fasting is defined as no caloric intake for at least 8 hours.) OR iii. 2-hour prandial glucose (PG) level of ≥ 200 mg/dL during an oral glucose tolerance test (OGTT).
  • Stable dose of metformin (at least 1500 mg daily [daily dose of at least 1000 mg is permitted if intolerant to 1500 mg dose]) for a period of at least 3 months prior to Screening
  • Eligible for initiation of or already receiving insulin glargine
  • ≥ 10.0 g/Dl
  • HbA1c of 7.5% to 10.0 %
  • of 18.5 to 35.0 kg/m2

Key Exclusion Criteria

  • Patients with T1DM
  • Treatment with glucagon-like peptide 1 agonists within 12 weeks prior to Screening
  • Ongoing treatment with OADs (eg, Thiazolidinediones) or unapproved for combination treatment with insulin
  • Presence of gastrointestinal (GI) disorders or conditions known to significantly alter the absorption of orally administered drugs or significantly alter upper GI or pancreatic function
  • History of ≥2 episodes of severe hypoglycemia (as per ADA 2017) within the 6 months before Screening
  • History of > 1 episode of hyperglycemic hyperosmolar coma or hospitalization for uncontrolled diabetes (eg, diabetic ketoacidosis); within the 6 months prior to Screening
  • cardiovascular and/or cerebrovascular disease within 12 months before Screening including, but not limited to unstable angina, myocardial infarction, Class III or Class IV congestive heart failure according to the criteria, valvular heart disease, cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, coronary angioplasty, stroke or .
  • Patients with the following secondary complications of diabetes:

    i. Active proliferative retinopathy as confirmed by a dilated ophthalmoscopy (by the investigator, site ophthalmologist or an optometrist; as per standard site practice) within 6 months prior to Screening. ii. Renal dysfunction indicated by modification of diet in renal disease estimated \< 45 mL/min/1.73 m2 and/or diabetic nephropathy and/or clinical nephrotic syndrome at Screening. iii. History or presence of severe form of neuropathy or signs and symptoms of severe cardiac autonomic neuropathy. iv. Patients with non-traumatic amputation (at any time) or clinically significant

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Insulin Tregopil (IN-105) - 45mg

    Strength of each tablet is 15mg

    Drug: Insulin Tregopil

  • Experimental
    Insulin Tregopil (IN-105) - 30mg

    Strength of each tablet is 15mg

    Drug: Insulin Tregopil

  • Active comparator
    Insulin Aspart

    Pre-filled pen: 100 U/L

    Drug: Insulin Aspart

Interventions

  • Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.

    Also known as: IN-105

  • Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c at 24 Weeks (Part 1)

    The primary endpoint is change from baseline in HbA1c after 24 weeks of randomized treatment.

    Time frame: Week 0, Week 24

Secondary outcomes

  1. Change From Baseline in HbA1c at Week 12 (Part 1)

    This secondary outcome is the change from baseline in HbA1c after 12 weeks of randomized treatment. For this endpoint baseline (Week 0) and Week 12 have been presented.

    Time frame: Week 0, Week 12

  2. Participants Achieving HbA1c < 7% (Part 1)

    Number of participants achieving HbA1c \< 7% at Week 12 and Week 24.

    Time frame: Week 12, Week 24

  3. Percentage of Participants With Hypoglycemia Events During 24-week Treatment Period (Part 1)

    A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\]

    Time frame: Week 0 through Week 24

  4. Weight (Kgs) (Part 1)

    Change from Baseline in weight (kgs) to 24 weeks

    Time frame: Week 0 and Week 24

  5. Lipid Profile (Part 1)

    Change from Baseline in lipid profile (triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol) to 24 weeks

    Time frame: 24 weeks

  6. Post-prandial Glucose (PPG) Excursion (Part 1)

    Change from Baseline in the mean 60, 90, 120 minutes PPG excursions assessed from standardized test meal at Week 24.

    Time frame: Week 0, Week 24

  7. Number of Participants With Treatment-Emergent Adverse Events (Part 1)

    Includes participants who have experienced at least one treatment emergent adverse events over 24 weeks

    Time frame: 24 weeks

  8. Anti-drug Antibody Levels

    Incidence and change from baseline in the relative levels of anti-drug antibody levels over 24 weeks

    Time frame: 24 weeks

  9. CGM

    Area under the glucose curve below 70 mg/dL derived from CGM, applicable for only part II study

    Time frame: 24 weeks

Other outcomes

  1. Participants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24

    Number of participants achieving HbA1c \< 7% at Week 12 and Week 24 without reported clinically significant or severe hypoglycemic events between end of Week 8 and Week 24.

    Time frame: Week 12, Week 24

07

Results

Posted May 15, 2020

Participant flow

Out of 20 sites, which were selected for recruitment, 19 sites enrolled subjects in the run-in period, of which 15 sites later assigned subjects to randomized treatment: India:20 sites

Participant flow — Overall Study
MilestoneInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Started313030
Exposed313030
Completed292729
Not completed231
Withdrew: Adverse event010
Withdrew: Rescue criteria110
Withdrew: Voluntary withdrawal of consent111

Outcome measures

PrimaryChange From Baseline in HbA1c at 24 Weeks (Part 1)

The primary endpoint is change from baseline in HbA1c after 24 weeks of randomized treatment.

Time frame:
Week 0, Week 24
Reported as:
Mean · Percentage of glycosylated hemoglobin
Change From Baseline in HbA1c at 24 Weeks (Part 1)
Percentage of glycosylated hemoglobinInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Baseline (Week 0)8.23 ± 0.5778.10 ± 0.6708.07 ± 0.697
Week 248.38 ± 1.1398.21 ± 0.9697.29 ± 0.788
Statistical analysis
  • Insulin Tregopil (IN-105) - 45mg vs Insulin Aspart · Mean difference (net): 0.99 · 95% CI 0.502 to 1.470Insulin Tregopil 45 mg - Insulin Aspart
  • Insulin Tregopil (IN-105) - 30mg vs Insulin Aspart · Mean difference (net): 0.89 · 95% CI 0.414 to 1.370Insulin Tregopil 30mg - Insulin Aspart
SecondaryChange From Baseline in HbA1c at Week 12 (Part 1)

This secondary outcome is the change from baseline in HbA1c after 12 weeks of randomized treatment. For this endpoint baseline (Week 0) and Week 12 have been presented.

Time frame:
Week 0, Week 12
Reported as:
Mean · Percentage of glycosylated haemoglobin
Change From Baseline in HbA1c at Week 12 (Part 1)
Percentage of glycosylated haemoglobinInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Baseline (Week 0)8.23 ± 0.5778.10 ± 0.6708.07 ± 0.697
Week 128.04 ± 0.9408.01 ± 0.8987.18 ± 0.810
Change from Baseline-0.17 ± 0.913-0.07 ± 0.866-0.88 ± 0.850
SecondaryParticipants Achieving HbA1c < 7% (Part 1)

Number of participants achieving HbA1c \< 7% at Week 12 and Week 24.

Time frame:
Week 12, Week 24
Reported as:
Count of participants · Participants
Participants Achieving HbA1c < 7% (Part 1)
ParticipantsInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Week 124313
Week 242210
SecondaryPercentage of Participants With Hypoglycemia Events During 24-week Treatment Period (Part 1)

A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\]

Time frame:
Week 0 through Week 24
Reported as:
Count of participants · Participants
Percentage of Participants With Hypoglycemia Events During 24-week Treatment Period (Part 1)
ParticipantsInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Percentage of Participants With Hypoglycemia Events During 24-week Treatment Period (Part 1)262625
SecondaryWeight (Kgs) (Part 1)

Change from Baseline in weight (kgs) to 24 weeks

Time frame:
Week 0 and Week 24
Reported as:
Mean · Kg
Weight (Kgs) (Part 1)
KgInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Baseline (Week 0)68.54 ± 11.55968.88 ± 9.04067.76 ± 9.628
Week2468.98 ± 11.83770.15 ± 8.91568.47 ± 9.761
Change from Baseline0.93 ± 1.2120.30 ± 1.9550.66 ± 1.807
SecondaryLipid Profile (Part 1)

Change from Baseline in lipid profile (triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol) to 24 weeks

Time frame:
24 weeks

No measurements were reported for this outcome.

SecondaryPost-prandial Glucose (PPG) Excursion (Part 1)

Change from Baseline in the mean 60, 90, 120 minutes PPG excursions assessed from standardized test meal at Week 24.

Time frame:
Week 0, Week 24
Reported as:
Mean · mg/dL
Post-prandial Glucose (PPG) Excursion (Part 1)
mg/dLInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Week 0, 60 min79.5 ± 45.5398.3 ± 41.9474.4 ± 42.85
Week 0, 90 min92.4 ± 47.94106.4 ± 35.3990.8 ± 35.35
Week 0, 120 min100.9 ± 58.18113.5 ± 53.4593.7 ± 41.20
Week 24, 60 min35.8 ± 44.2632.7 ± 45.1355.1 ± 34.57
Week 24, 90 min53.8 ± 45.3847.2 ± 44.8466.3 ± 36.13
Week 24, 120 min64.1 ± 51.8750.2 ± 44.2365.5 ± 34.58
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (Part 1)

Includes participants who have experienced at least one treatment emergent adverse events over 24 weeks

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (Part 1)
ParticipantsInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Number of Participants With Treatment-Emergent Adverse Events (Part 1)564
SecondaryAnti-drug Antibody Levels

Incidence and change from baseline in the relative levels of anti-drug antibody levels over 24 weeks

Time frame:
24 weeks

No measurements were reported for this outcome.

SecondaryCGM

Area under the glucose curve below 70 mg/dL derived from CGM, applicable for only part II study

Time frame:
24 weeks

No measurements were reported for this outcome.

Other pre-specifiedParticipants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24

Number of participants achieving HbA1c \< 7% at Week 12 and Week 24 without reported clinically significant or severe hypoglycemic events between end of Week 8 and Week 24.

Time frame:
Week 12, Week 24
Reported as:
Count of participants · Participants
Participants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24
ParticipantsInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
Week 124311
Week 24137

Adverse events

Collected over From the date on or after first day of exposure to randomized treatment until the last day of randomized treatment, an average of 24 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Tregopil (IN-105) - 45mg0/31 (0%)0/31 (0%)5/31 (16.1%)
Insulin Tregopil (IN-105) - 30mg0/30 (0%)0/30 (0%)5/30 (16.7%)
Insulin Aspart0/30 (0%)0/30 (0%)4/30 (13.3%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventInsulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin Aspart
GastritisGastrointestinal disorders1/311/300/30
NauseaGastrointestinal disorders0/310/301/30
PyrexiaGeneral disorders1/311/300/30
Urinary tract infectionInfections and infestations0/311/300/30
DysenteryInfections and infestations0/311/300/30
Upper respiratory tract infectionInfections and infestations0/311/300/30
FallInjury, poisoning and procedural complications0/310/301/30
Vulval lacerationInjury, poisoning and procedural complications0/310/301/30
Hepatic enzyme increasedInvestigations0/311/300/30
Decreased appetiteMetabolism and nutrition disorders0/310/301/30

Baseline characteristics

Safety Analysis Set included all randomized subjects.

Age, Continuous
Age, Continuous(Year)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
Mean52.1 ± 9.4950.9 ± 9.4454.5 ± 8.1852.5 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
Female15141443
Male16161648
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
American Indian or Alaska Native0000
Asian31303091
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
India31303091
Weight
Weight(kg)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
Mean68.54 ± 11.55968.88 ± 9.04067.76 ± 9.62868.39 ± 10.048
Height
Height(cm)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
Mean158.84 ± 7.987158.76 ± 9.268158.20 ± 9.321158.60 ± 8.776
BMI
BMI(kg/m^2)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
Mean27.13 ± 3.86627.39 ± 3.41827.13 ± 3.66727.22 ± 3.618
Duration of T2DM
Duration of T2DM(years)Insulin Tregopil (IN-105) - 45mgInsulin Tregopil (IN-105) - 30mgInsulin AspartTotal
Mean8.78 ± 7.8677.83 ± 7.7158.12 ± 6.7888.25 ± 7.404

6 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Diacon Hospital
    Bangalore, Karnataka 560010, India
09

References and documents

Publications

  • Lebovitz HE, Fleming A, Cherrington AD, Joshi S, Athalye SN, Loganathan S, Vishweswaramurthy A, Panda J, Marwah A. Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study. Expert Opin Pharmacother. 2022 Nov;23(16):1855-1863. doi: 10.1080/14656566.2022.2141569. Epub 2022 Nov 9. PubMed 36352762 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Feb 2019, 13 months.

Results were first posted in May 2020, 1 year 3 months after primary completion.

Of 32 phase 2/3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Feb 13, 2018
StartActual
Dec 26, 2017
Primary completionActual
Feb 6, 2019
CompletionActual
Feb 20, 2019
Results first posted
May 15, 2020
Last update
May 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03430856
Lead sponsor
Biocon Limited
Responsible party
Sponsor
First posted
Feb 13, 2018
Start date
Dec 26, 2017
Primary completion
Feb 6, 2019
Completion
Feb 20, 2019
Results posted
May 15, 2020
Last update
May 15, 2020

Study contacts

Subramanian Loganathan, MD
study director · Biocon Research Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin tregopil

Start the discussion